RACHEL SAVAGE: Open Payments
NPI 1588209779 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,763 in 53 payments from 26 companies in 2025. Trend: 2023 $2,022 · 2024 $2,631 · 2025 $1,763
Food & beverage: $1,165Long term medical supply or device loan: $598
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 8 | $643 |
| Celgene Corporation | 4 | $113 |
| Incyte Corporation | 4 | $101 |
| SOBI, INC | 3 | $85 |
| Merck Sharp & Dohme LLC | 3 | $80 |
| Janssen Biotech, Inc. | 3 | $76 |
| Deciphera Pharmaceuticals Inc. | 2 | $61 |
| Lilly USA, LLC | 2 | $60 |
| AstraZeneca Pharmaceuticals LP | 2 | $55 |
| ARRAY BIOPHARMA INC | 3 | $54 |
Products named: KISQALI, REBLOZYL, KEYTRUDA, Doptelet, VERZENIO, CALQUENCE, BRAFTOVI, JAKAFI.
Industry payments across TX — which companies pay providers there.
